Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events | Zendy

Antonios Douros | Zendy; Hui Yin | Zendy; Oriana Hoi Yun Yu | Zendy; Kristian B. Filion | Zendy; Laurent Azoulay | Zendy; Samy Suissa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

Author(s) -

Antonios Douros,

Hui Yin,

Oriana Hoi Yun Yu,

Kristian B. Filion,

Laurent Azoulay,

Samy Suissa

Publication year - 2017

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc17-0595

Subject(s) - medicine , glimepiride , glipizide , gliclazide , hypoglycemia , tolbutamide , hazard ratio , diabetes mellitus , sulfonylurea , stroke (engine) , myocardial infarction , type 2 diabetes , adverse effect , proportional hazards model , insulin , cohort , cardiology , endocrinology , confidence interval , mechanical engineering , engineering

Sulfonylureas have been associated with an increased risk of cardiovascular adverse events and hypoglycemia, but it is unclear if these risks vary with different agents. We assessed whether the risks of acute myocardial infarction, ischemic stroke, cardiovascular death, all-cause mortality, and severe hypoglycemia differ between sulfonylureas grouped according to pancreas specificity and duration of action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research